Glenmark Pharma unveils lower cost alternative to Bumex Injection

Written by Ruchika Sharma Published On 2023-01-11T12:23:09+05:30 | Updated On 13 Oct 2023 4:41 PM IST

Glenmarks Telma Surpasses Rs 1,000 Crore Revenue, Recognized in Harvard Case Study

Mumbai: Glenmark Pharmaceuticals Inc., USA has announced that the company has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials.

The product is a generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy said, “We are very pleased to bring to market a lower cost alternative to Bumex Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”

According to IQVIA sales data for the 12-month period ending November 2022, the Bumex Injection, 0.25 mg/mL market achieved annual sales of approximately $16.5 million*.

Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA.

"In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio," Glanmark stated.

Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year.

Read also: Glenmark Pharma bags USFDA nod for high BP drug Nicardipine Hydrochloride

glenmark pharmaglenmark pharma newsBumetanide InjectionBumex InjectionValidus Pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751